135654-16-9

Basic information

• Product Name: 3-(CHLOROMETHYL)BENZAMIDE
• Synonyms: 3-(CHLOROMETHYL)BENZAMIDE;Benzamide, 3-(chloromethyl)- (9CI);3-Carbamoylbenzyl chloride, 3-(Aminocarbonyl)benzyl chloride
• CAS NO: 135654-16-9
• Molecular Formula: C₈H₈ClNO
• Molecular Weight: 169.61
• Product Categories: HALOMETYL
• Mol File: 135654-16-9.mol
• Article Data: 7

Chemical Properties

• Melting Point: 123-127
• Boiling Point: 311.614 °C at 760 mmHg
• Flash Point: 142.259 °C
• Appearance: /
• Density: 1.249 g/cm³
• Vapor Pressure: 0.000557mmHg at 25°C
• Refractive Index: 1.575
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 3-(CHLOROMETHYL)BENZAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(CHLOROMETHYL)BENZAMIDE(135654-16-9)
• EPA Substance Registry System: 3-(CHLOROMETHYL)BENZAMIDE(135654-16-9)

Safety Data

• Hazard Codes: C
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 135654-16-9(Hazardous Substances Data)

Usage

General Description

3-(Chloromethyl)benzamide, also known by its chemical formula C8H8ClNO, is a benzamide derivative that contains a chlorine atom attached to the carbon in the third position of the benzene ring. It is used in pharmaceutical and organic synthesis as a building block for the production of various compounds. This chemical is also known for its potential use in medicinal chemistry, specifically in the development of drugs and bioactive molecules. Due to its structure and properties, 3-(Chloromethyl)benzamide has a wide range of applications in research and industry.

InChI:InChI=1/C8H8ClNO/c9-5-6-2-1-3-7(4-6)8(10)11/h1-4H,5H2,(H2,10,11)

Upstream product

• 64407-07-4 3-(chloromethyl)benzonitrile 
• 63024-77-1 3-(Chloromethyl)benzoyl chloride 
• 1097010-28-0 C₁₅H₁₄ClNO 
• 31719-77-4 3-chloromethylbenzoic acid 

Downstream Products

• 52059-72-0 5-(3-chloromethyl-phenyl)-[1,3,4]oxathiazol-2-one 
• 1002093-66-4 3-[5-amino-6-(2,3-dichloro-phenyl)-3-imino-3H-[1,2,4]triazin-2-ylmethyl]-benzamide 
• 135654-24-9 3-carbamoyl benzylsulfonylacetic acid 
• 135654-04-5 3-((E)-2-Phenyl-ethenesulfonylmethyl)-benzamide 
• 135654-05-6 3-((E)-2-p-Tolyl-ethenesulfonylmethyl)-benzamide 
• 135654-06-7 3-[(E)-2-(4-Bromo-phenyl)-ethenesulfonylmethyl]-benzamide 
• 52059-78-6 5-(3-iodomethyl-phenyl)-[1,3,4]oxathiazol-2-one 
• 64407-07-4 3-(chloromethyl)benzonitrile 
• 1043908-22-0 3-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-methyl-2-oxo-3-m-tolyl-2,3-dihydro-1H-imidazol-1-yl)methyl)benzamide 
• 1240518-75-5 C₂₆H₃₁ClN₄O₅S₂Si 
• 1240518-13-1 C₂₄H₁₈N₄O₄ 
• 1240518-82-4 C₂₄H₁₇FN₄O₄ 

Relevant articles and documents

MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF

Hydantoin based compounds useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.

NEW MEDICAL USE OF TRIAZINE DERIVATIVES

-

Synthesis of 3-substituted benzamides and 5-substituted isoquinolin-1(2H)-ones and preliminary evaluation as inhibitors of poly(ADP-ribose)polymerase (PARP)

Inhibitors of poly(ADP-ribose)polymerase (PARP) inhibit repair of damaged DNA and thus potentiate radiotherapy and chemotherapy of cancer. 3-Substituted benzamides and 5-substituted isoquinolin-1-ones have been synthesised and evaluated for inhibition of PARP. Reduction of 3-(bromoacetyl)benzamide, followed by treatment with base, gave RS-3-oxiranylbenzamide. Reduction of 3-(hydroxyacetyl)benzonitrile with bakers' yeast gave the R-diol which was converted to R-3-(1,2-dihydroxyethyl)benzamide. Similar reduction of 3-(acetoxyacetyl)benzonitrile led towards the S-diol which was converted to its cyclic acetonide. E-2-(2,6-Dicyanophenyl)-N,N-dimethylethenamine was formed by condensation of 2,6-dicyanotoluene with dimethylformamide dimethyl acetal (DMFDMA); cyclisation under acidic conditions afforded 5-cyanoisoquinolin-1-one. Heck coupling of 5-iodoisoquinolin-1-one with propenoic acid formed E-3-(1-oxoisoquinolin-5-yl)propenoic acid. 3-Oxiranylbenzamide, 5-bromoisoquinolin-1-one and 5-iodoisoquinolin-1-one were among the most potent inhibitors of PARP activity in a preliminary screen in vitro. Copyright (C) 1998 Elsevier Science Ltd.